ClinicalTrials.gg

Epilepsies, Partial clinical trials

Its pipeline, or its studies — you choose. Free with an account during the beta.

The registry lists 243 studies for Epilepsies, Partial across more than 10 countries. 49 are recruiting or about to start. 186 of them are mainly about Epilepsies, Partial (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-16. Counting its 2 narrower conditions too, such as Epilepsy, Temporal Lobe: 323 studies, 73 open.

Status

Completed
138
Recruiting
37
Terminated
22
Status unknown
16
Active, not recruiting
9
Withdrawn
7

Phase

Phase 3
68
Phase 2
46
Phase 4
30
Phase 1
10
Early Phase 1
2

Where

United States
102
France
40
Germany
33
Poland
26
Australia
22
Spain
22

Who develops what

Add Epilepsies, Partial to watchlistPro · free during the betaEvery Monday by email · turn it off any time

Every program with a company-led study here in the last two years, whatever its size: 5 programs from 5 companies, 4 with this as their studies’ main aim; 2 with a live phase 3 study; 3 primary completions in the next 12 months. Compare Qingfeng Pharmaceutical Group and Supernus Pharmaceuticals here →

Comparator & background therapies

What other companies’ phase 2+ studies give as the comparator or the background here (its leading trial sponsor and partners left out): a sign of what new drugs are measured against, not by itself the standard of care, its prescriptions or its market.

None given by two companies or more yet.

Programs

“Meets, by arms” reads each study’s arms: vs its arm against the therapy’s; + X vs a combination against it; added to it plus the therapy against the therapy; studied with given together only. The next primary completion is the next phase-3 study’s when there is one.

The 5 programs — sign in to see the whole list, free: filter by phase and aim, sort by late development, direct comparisons or the next primary completion.

Primary completion in the next 12 months (3)

Live phase 2 and 3 studies of these programs. Primary completion is when the main measure’s data collection ends, as the registry states it (most are estimates); results come later, if they are announced.

  • Jan 2027 est.40 mg/day vormatrogine for 12 weeks · Praxis Precision Medicines · Phase 3 main aimNCT07505004 Randomized Clinical Trial Evaluating the Efficacy and Safety of Vormatrigine in Adults With Focal Seizures — primary endpoint: To evaluate the efficacy of vormatrigine compared to placebo on focal seizure frequency in adults currently taking 1 to 3 ASMs · 300 enrolled
  • Aug 2027 est.SPN-817 · Supernus Pharmaceuticals, Inc. · Phase 2 registry mapping onlyNCT06798896 RENAISSANCE 2: SPN-817 Phase 2, Double-Blind, Placebo-Controlled Study in Adults With Focal Onset Seizures — primary endpoint: Percent change (PCH) from baseline in focal onset seizure frequency per 28 days over the Maintenance Period · 216 enrolled
  • Sep 2027 est.CB03-154 · Shanghai Zhimeng Biopharma, Inc. · Phase 2 main aimNCT06612775 A Study to Evaluate the Safety, Tolerability, and Efficacy of CB03-154 in Adult Patients With Focal Epilepsy — primary endpoint: To assess the efficacy of CB03-154 compared to placebo on focal seizure frequency in adults with focal epilepsy taking 1 to 3 AEDs in the double-blind period (DBP). · 180 enrolled

Read from ClinicalTrials.gov, industry-led studies. Main aim: this is the study’s judged main condition; named, not the main aim: the sponsor names it, the study is about something else; registry mapping only: only the registry’s mapping put it here. Leading trial sponsor is the company leading the most industry studies of a drug, a measure of trial activity, not of rights. US and EU rights, and Approved: from the regulators’ records (FDA’s Drugs@FDA via openFDA; EMA’s medicines data) — the holder of a marketed or authorized original, generics and other companies’ versions; not rights elsewhere, nor approval for this condition. Phase 4 trial recorded, where neither lists it: a phase 4 study exists somewhere. Not read yet: labels by indication, exclusivity, licenses, line of therapy, academic comparators, sales.

What is being tested here

Drugs under test in Epilepsies, Partial studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Drug classes tested here Anxiolytics 3

Coming up

19studies finish main data collection within a year2 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

The 10 nearest, phase 3 first

Who these studies take

Of the 37 Epilepsies, Partial studies recruiting now, 9 (24%) set no upper age limit and 24 (65%) stop at 75 or younger. 17 (46%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 3 (8%) take healthy volunteers.

Recruiting studies that take each age, of 37
AgeWomenMen
1015 (41%)15 (41%)
1832 (86%)32 (86%)
3028 (76%)28 (76%)
4028 (76%)28 (76%)
5027 (73%)27 (73%)
6524 (65%)24 (65%)
7516 (43%)16 (43%)
8512 (32%)12 (32%)

Across all 243 studies, recruiting or not: 55% stop at 75 or younger and 41% at 65; 46% take children; <1% are for women only and 1% for men only; 9% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

What changed recently

From the registry's own updates since Oct 18, 2026.

Studies

Recruiting first, then most recently updated. Showing 50 of 243. Browse all 243 → or search them.